These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14600095)

  • 21. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
    Roh JL; Kim EH; Park HB; Park JY
    Cell Death Dis; 2013 Dec; 4(12):e956. PubMed ID: 24336076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
    Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
    Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D; Shieh B; Yan C; Kepa JK; Ross D
    J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels.
    Braga-Basaria M; Hardy E; Gottfried R; Burman KD; Saji M; Ringel MD
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2982-8. PubMed ID: 15181088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Maloney A; Clarke PA; Naaby-Hansen S; Stein R; Koopman JO; Akpan A; Yang A; Zvelebil M; Cramer R; Stimson L; Aherne W; Banerji U; Judson I; Sharp S; Powers M; deBilly E; Salmons J; Walton M; Burlingame A; Waterfield M; Workman P
    Cancer Res; 2007 Apr; 67(7):3239-53. PubMed ID: 17409432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X; Zhang H; Burrows F; Zhang L; Shores CG
    Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
    Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
    Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
    Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
    Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
    Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
    Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM; Fiebig HH; Stinson SF; Sausville EA
    Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy.
    Pan C; Zhang T; Li S; Xu Z; Pan B; Xu S; Jin S; Lu G; Yang S; Xue Z; Chen P; Shen X; Wang F; Xu C
    Int J Nanomedicine; 2021; 16():1743-1755. PubMed ID: 33688189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
    Williams CR; Tabios R; Linehan WM; Neckers L
    J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
    Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.